ASH leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.
Subcommittee on Clinical Trials
The Subcommittee on Clinical Trials (under the purview of the Committee on Scientific Affairs) identifies prominent barriers to the design of clinical trials for hematologic diseases, determines ways ASH could play a role in overcoming such barriers, and if appropriate, makes recommendations to the Society.
Subcommittee on Emerging Gene and Cell Therapies
Improving immune-based therapies for hematologic diseases is one of ASH’s research priorities. As the body of evidence continues to grow on the potential applications of these therapies, next-generation research must focus on the possible curative effects while also addressing the multiple challenges that still need to be overcome to ensure their optimal use.
Subcommittee on Precision Medicine
The Subcommittee on Precision Medicine (under the purview of the Committee on Scientific Affairs) aims to improve the use of genomic data in clinical care, research, and education.
ASH Agenda for Hematology Research
The ASH Agenda for Hematology Research serves as a roadmap to prioritize research within the hematology field. In it, we identify key emerging and transformative areas of research that will launch the field into the next generation of therapies for hematologic conditions.
Resources for PhDs
ASH is committed to supporting the participation of basic science-trained investigators in hematologic research and in promoting their participation in the Society’s activities. Below, please find resources, awards, and opportunities for committee and leadership positions for basic scientists involved in hematology-focused research.
Precision Medicine Initiative
Precision medicine encompasses all approaches that use patient- and disease-specific information to prevent, diagnose, and treat a disease. The increasingly widespread use of genome sequencing and genomic profiling has significantly improved the diagnoses and treatment of hematologic diseases by identifying unique variants that can be targeted with gene-based targeted therapeutic approaches including immunotherapies.
Applying the principles of precision medicine to hematologic diseases is a priority for ASH, and specific research recommendation are described in more detail in the ASH Agenda for Hematology Research.
Learn more about ASH's Precision Medicine Initiative activities:
Molecular profiling of DNA and RNA has provided valuable new insights into the genetic basis of non-malignant and malignant hematologic disorders as well as an increased understanding of basic mechanisms that regulate hematopoiesis. Read more.
The field of immunology has generated novel immune-based strategies and improved the utility of existing treatment options for various hematologic diseases.” It should still link to the original page that it links to now. Read more.
Programs and Awards for Research
ASH supports basic, clinical, and translational hematology investigators at all levels of their careers through its many research award and grant programs.
As a demonstration of its commitment to protecting the field and those who have dedicated their careers to the specialty, ASH has established the Bridge Grant to help preserve the careers of its talented member scientists whose vital research will not be accomplished due to across-the-board cuts to the National Institutes of Health (NIH) budget. Read more.
The ASH Clinical Research Training Institute (CRTI) is a unique, year-long education and mentoring program for hematology fellows and junior faculty at academic medical centers. CRTI offers a broad education on clinical research methods, research collaborations, statistical analysis, and managing the demands of family and career. The goal of the program is to produce leaders armed with ideas for clinical hematology research and the tools and resources to make their ideas a reality. Read more.
A joint effort of the American Society of Hematology (ASH) and the European Hematology Association (EHA), Translational Research Training in Hematology (TRTH) is a unique, year-long training and mentoring program focused on helping early stage researchers, including senior postdoctoral fellows and junior faculty, gain the tools necessary to build successful careers in blood-related translational research. Read more.
The Minority Medical Student Award Program (MMSAP) is structured around research experiences of various lengths for students from the United States and Canada in their early years of medical school. Each year, up to 10 minority medical students enrolled in DO, MD, or MD/PhD programs are selected to participate. Read more.
The Physician-Scientist Career Development Award immerses medical students between their first and second or second and third years of school in a one-year, full-time research experience in hematology. Read more.
The ASH Research Training Award for Fellows (RTAF) is designed to encourage junior researchers in hematology, hematology/oncology, and other hematology-related training programs to pursue a career in academic hematology. Read more